神經血管血栓管理市場規模、佔有率和趨勢分析 |全球| 2026–2032 |目標產品：血栓摘取支架栓器、吸管和其他一種產品。

2025年全球神經血管血栓治療市場價值為16億美元。預計該市場將以5.7%的複合年成長率成長，到2032年達到24億美元。

本報告涵蓋用於急性缺血性腦中風機械治療的血栓摘取支架、抽吸導管和抽吸幫浦槽。報告基於截至2022年的歷史數據和截至2032年的預測數據，對手術例數、銷量、平均售價、市場規模、成長率和企業市場占有率進行了定量分析。

MR CLEAN、ESCAPE、EXTEND-IA 和 SWIFT PRIME 等突破性臨床試驗已確立機械取栓術作為合格的急性缺血性腦中風患者的標準治療方案，加速了醫生對該療法的接受度，並擴大了治療人群。卒中是全球第二大死因和首要致殘原因，其中 87% 為缺血性卒中。許多合格的患者仍未接受取栓術，這代表著巨大的市場機會，但市場滲透率卻極低。

准入和基礎設施方面的限制阻礙了市場發展的步伐。由於合格中風治療中心數量有限、發病後8小時內必須接受治療以及患者轉運和治療團隊組成的延誤，相當一部分符合條件的患者無法接受機械取栓治療。在預測期內，解決這個准入缺口將是充分發揮市場成長潛力的關鍵挑戰。

市場概覽

全球神經血管血栓治療市場主要關注透過機械方法清除或破壞因大血管閉塞引起的急性缺血性腦中風患者的血栓。在多項隨機對照試驗證實其優於單純藥物治療後，使用血栓摘取支架和抽吸導管進行機械取栓已成為合格患者的標準治療方案。自這些試驗達成臨床共識以來，隨著器械技術和手術效率的不斷提高，全球治療量持續成長，市場規模顯著擴大。

機械取栓技術的進步提高了治療效率和患者預後，促進了其在臨床實踐中的廣泛應用。新一代血栓摘取支架和改良的抽吸技術縮短了手術時間，降低了併發症發生率，使更多醫療機構和臨床團隊能夠進行此類治療。支援大口徑導管技術的抽吸幫浦系統也逐漸成為重要的手術方式，可與血栓摘取支架在獨立或合併治療中相輔相成。這些進步共同凸顯了取栓術在日益多元化的患者群體中的臨床療效。

符合機械取栓術適應症的患者群體範圍廣泛，且仍在擴大。中風是全球第二大死因，也是導致長期殘疾的主要原因。預計到2030年，中風盛行率將增加約20%，這主要是由於人口老化所致。由於87%的中風為缺血性中風，因此符合取栓術適應症的潛在患者數量龐大。 2021年的一項研究發現，約48.7%的缺血性中風患者最初在取栓中心接受治療，顯示仍有相當一部分合格的患者未能獲得這種治療。

基礎設施的限制正在減緩市場發展的步伐。配備設施、人員和手術能力的中風專科治療中心主要集中在都市區，導致廣大農村和郊區人口無法直接獲得醫療服務。雖然大多數血栓除去裝置都適用於症狀出現後八小時內使用，但由於患者就診延遲、院際轉運、診斷延誤以及訓練有素的卒中團隊組建滯後等原因，這一治療窗口期往往被錯過。為了最大限度地發揮該市場的成長潛力，擴大卒中中心網路並改善區域醫療服務路徑至關重要。

市場促進因素

臨床試驗結果良好

多項突破性臨床試驗已證實，對於合格的急性缺血性腦中風患者，機械性取栓合併藥物治療優於單純藥物治療。關鍵研究包括在荷蘭進行的MR CLEAN試驗、針對小核心近端閉塞缺血性中風患者的ESCAPE試驗、透過動脈內治療延長溶栓治療時間的EXTEND-IA試驗，以及評估Solitaire裝置作為第一線血管內治療的SWIFT PRIME試驗。這些試驗的綜合證據正促使醫師採用血栓除去裝置，機械取栓在大血管閉塞性中風治療中正逐漸成為標準治療方法。隨著依證的不斷擴展和指南建議的更新，預計臨床應用將進一步擴大，從而推動血栓摘取支架和抽吸導管領域的銷售和市場價值持續成長。

市場滲透率低

中風在全球範圍內的高發病率，以及其中絕大多數為缺血性中風的事實，造就了一個巨大的未開發市場，其市場滲透率卻極低。中風是全球第二大死因和首要殘疾原因。此外，隨著全球人口老化，預計到2030年，中風的發生率將增加約20%。由於87%的中風為缺血性中風，因此能夠從機械取栓術中獲益的患者數量遠遠超過目前實際進行的手術數量。截至2021年，約48.7%的缺血性中風患者在取栓中心接受了初始治療，合格的患者與實際接受治療的患者之間的差距，是治療量成長的重要來源，尤其是在新興市場，介入神經放射學。

市場限制

治療時間的限制

機械取栓術僅在卒中症狀出現後的指定時限內有效，大多數器械的適應症為症狀出現後8小時內。此時限限制限制了可從該手術中獲益的患者總數，因為許多患者無法在規定時限內到達能夠進行取栓術的醫療機構。治療流程中的多個環節都存在延誤，包括患者的初次就診、急診評估、影像檢查、取栓設備的準備以及訓練有素的中風團隊的組成。改善醫療基礎設施、加強院前分診或研發治療時間更長的器械，將有助於擴大合格的患者群體，並增加手術數量，但在目前的框架下，這一時間限制是市場擴張的一個重大結構性限制因素。

中風治療中心數量有限

取栓術只能在配備專業中風中心、必要的神經血管設備和訓練有素的介入團隊的醫院進行。由於這些設施集中在都市區，許多居住在農村或郊區的患者無法直接接受治療。即使都市區患者最初就診於沒有卒中中心的醫院，也需要轉診，這會在原本就有限的治療時限內浪費寶貴的時間。大多數血栓除去裝置都是按需訂購，而不是由醫院儲備，這進一步延長了從病患合格評估到器械取得的時間。在預測期內，解決這些限制的主要方法是擴大中風救治機構網路並改善跨區域患者轉診流程。

目錄

調查方法

• 第一步：專案啟動與團隊組建
• 步驟二：資料系統開發與二次調查實施
• 步驟三：準備面試設計問卷
• 第四步：進行初步調查
• 第五步：調查分析：基準估計
• 第六步：市場預測與分析
• 第七步：辨識策略機遇
• 步驟 8：最終確認和市場發布
• 步驟九：客戶回饋與市場監測

全球關稅的影響

神經血管血栓管理市場

• 執行摘要
  • 全球神經血管血栓管理市場概覽
  • 競爭分析
  • 涵蓋的治療
  • 目標市場
  • 目標區域
• 介紹
• 步驟數
• 市場概覽
  • 按細分市場
  • 按地區
• 市場分析與預測
  • 神經血管血栓管理市場整體狀況
  • 血栓摘取支架市場
  • 吸痰導管市場
  • 吸泵、罐體和導管市場
• 促進因素和抑制因素
  • 市場促進因素
  • 市場限制因素
• 競爭對手市佔率分析

附錄

The global neurovascular thrombus management market was valued at $1.6 billion in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 5.7%, reaching $2.4 billion by 2032.

This report covers stent retrievers, aspiration catheters, and aspiration pump canisters used in the mechanical treatment of acute ischemic stroke. The report quantifies procedure numbers, unit sales, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.

Multiple landmark clinical trials, including MR CLEAN, ESCAPE, EXTEND-IA, and SWIFT PRIME, have established mechanical thrombectomy as a standard of care for eligible acute ischemic stroke patients, driving physician adoption and expanding the procedural base. Stroke is the second leading cause of death and the leading cause of disability globally, with 87% of strokes classified as ischemic. A large proportion of eligible patients still do not receive thrombectomy treatment, representing a significant underpenetrated market opportunity.

Access and infrastructure constraints limit the pace of market realization. The restricted availability of specialized stroke treatment centers, treatment windows of up to eight hours after symptom onset, and delays in patient transfer and team assembly prevent a meaningful share of eligible patients from receiving mechanical thrombectomy. Closing this access gap is the central challenge to fully capturing the market's growth potential over the forecast period.

Market Overview

The global neurovascular thrombus management market addresses the mechanical removal or disruption of blood clots in patients with acute ischemic stroke caused by large vessel occlusion. Mechanical thrombectomy using stent retrievers and aspiration catheters has become the standard interventional treatment for eligible patients following the publication of multiple randomized controlled trials demonstrating its superiority over medical therapy alone. The market has grown substantially since these trials established clinical consensus, and continued improvements in device technology and procedure efficiency are supporting further expansion of treatment volumes globally.

Advances in mechanical thrombectomy technologies are enhancing treatment efficiency and patient outcomes, encouraging wider clinical adoption. Next-generation stent retrievers and improvements in aspiration techniques are reducing procedure time and complication rates, making these treatments more accessible to a broader range of centers and clinical teams. Aspiration pump systems supporting large-bore catheter techniques have also emerged as an important procedural category, complementing stent retrievers in both standalone and combined approaches. Together, these advances are reinforcing the clinical case for thrombectomy across a growing range of patient profiles.

The addressable patient population for mechanical thrombectomy is large and growing. Strokes are the second leading cause of death globally and the leading cause of long-term disability. The prevalence of stroke is expected to rise by approximately 20% by 2030, driven largely by aging demographics. Because 87% of strokes are ischemic, the potential patient volume for thrombectomy-eligible cases is substantial. A 2021 study found that approximately 48.7% of ischemic stroke patients initially received care at a thrombectomy hub, indicating that a significant portion of eligible patients still do not receive access to this treatment.

Infrastructure limitations temper the pace of market realization. Specialized stroke treatment centers with the equipment, staffing, and procedural volume to perform thrombectomy are concentrated in urban areas, leaving large rural and suburban populations without direct access to care. Most thrombectomy devices are indicated for use within eight hours of symptom onset, a window that is frequently missed due to delays in patient presentation, transfer between facilities, diagnosis, and assembly of a trained stroke team. Expanding the network of capable stroke centers and improving regional care pathways are necessary conditions for unlocking the full growth potential of this market.

Market Drivers

Favorable Clinical Trial Results

Multiple landmark clinical trials have established the clinical superiority of mechanical thrombectomy combined with medical therapy over medical therapy alone for eligible acute ischemic stroke patients. Key studies include the MR CLEAN trial in the Netherlands, the ESCAPE trial for patients with small core and proximal occlusion ischemic stroke, the EXTEND-IA trial extending the time frame for thrombolysis with intra-arterial treatment, and the SWIFT PRIME trial evaluating the Solitaire device as primary endovascular treatment. The combined weight of evidence from these trials has driven physicians to adopt thrombectomy devices and is moving mechanical thrombectomy toward standard of care status for large vessel occlusion stroke. As this evidence base continues to grow and guideline recommendations are updated, clinical adoption is expected to expand further, driving sustained unit sales and market value growth across the stent retriever and aspiration catheter segments.

Low Market Penetration

The global prevalence of stroke and the large proportion of strokes that are ischemic in nature create a substantial addressable market that remains significantly underpenetrated. Strokes are the second leading cause of death and the leading cause of disability worldwide, and their prevalence is expected to increase by approximately 20% by 2030 as global populations age. Because 87% of strokes are ischemic, the pool of patients who could in principle benefit from mechanical thrombectomy is very large relative to the number of procedures currently performed. With approximately 48.7% of ischemic stroke patients receiving initial care at a thrombectomy hub as of 2021, the gap between eligible patients and treated patients represents a meaningful source of volume growth as stroke care infrastructure continues to develop, particularly in emerging markets where access to neurointerventional care is expanding.

Market Limiters

Limited Treatment Window

Mechanical thrombectomy is effective only within a defined time window following stroke symptom onset, with most devices indicated for use within eight hours. This treatment window constraint limits the total number of patients who can benefit from the procedure, as many do not reach a facility capable of performing thrombectomy within the required timeframe. Delays occur at multiple points in the care pathway, including initial patient presentation, emergency assessment, diagnostic imaging, procurement of the thrombectomy equipment, and assembly of a trained stroke team. Any improvement in healthcare infrastructure, pre-hospital triage, or the development of devices with extended treatment windows would increase the eligible patient population and support procedural volume growth, but within the current framework this time constraint remains a significant structural ceiling on market expansion.

Limited Stroke Treatment Centers

Thrombectomy procedures can only be performed at hospitals with specialized stroke centers, the necessary neurovascular equipment, and a trained interventional team. These facilities are heavily concentrated in urban areas, leaving substantial rural and suburban patient populations without direct access to care. Even when patients in urban areas initially present to a hospital without stroke center capabilities, they must be transferred, which consumes critical time within the already narrow treatment window. Most thrombectomy devices are ordered on an as-needed basis by hospitals rather than held in standing inventory, adding further time between patient eligibility determination and device availability. Expanding the network of stroke-capable facilities and improving regional patient transfer protocols are the primary levers available to address this constraint over the forecast period.

Market Coverage and Data Scope

• Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
• Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and technology trends shaping demand.
• Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
• Data sources: Primary interviews with neurovascular device industry leaders and interventional neurologists, regulatory data, hospital procurement data, import and export data, and the iData Research internal database.
• Care settings: Hospitals and comprehensive stroke centers.

Markets Covered and Segmentation

• The neurovascular thrombus management market is analyzed across three device categories, each assessed by procedure volume, unit volume, ASP, and market value with historical and forecast data:
• Stent Retrievers
• Aspiration Catheters
• Aspiration Pump Canisters

Competitive Analysis

Medtronic was the leader in the global neurovascular thrombus management market in 2025. The company competes primarily through its Solitaire Flow Restoration Device, a stent retriever that played a central role in the SWIFT PRIME clinical trial and has accumulated one of the strongest evidence bases among mechanical thrombectomy devices. The Solitaire platform's clinical heritage and physician familiarity across major stroke centers globally underpin Medtronic's leadership position in this market, supported by the company's broad neurovascular distribution network and established relationships with comprehensive stroke programs.

Stryker held the second-leading position in the neurovascular thrombus management market in 2025. The company offers the Trevo ProVu Retrieval System, which incorporates Stentriever technology designed to allow physicians to fully visualize the device during both placement and retrieval under fluoroscopy. This visibility feature supports precise deployment and real-time assessment of thrombus engagement, contributing to procedural confidence and consistency. Stryker's established commercial presence in the broader neurovascular space reinforces its competitive position in the thrombectomy segment.

Penumbra was the third-leading competitor in the neurovascular thrombus management market in 2025. The company competes through the 3D Revascularization Device and its seventh-generation reperfusion catheter, the JET 7. Penumbra has been a significant contributor to the development and commercialization of aspiration-based thrombectomy techniques, positioning the company strongly within the aspiration catheter segment. The continued evolution of its catheter platform across successive generations reflects Penumbra's sustained investment in the thrombus management space and supports its competitive position alongside stent retriever-focused competitors.

Technology and Practice Trends

• Next-generation stent retrievers: Continued development of stent retriever designs with improved thrombus engagement, visibility, and ease of deployment is reducing procedure complexity and supporting consistent revascularization outcomes across a wider range of operator experience levels.
• Aspiration technique advancement: Large-bore aspiration catheters and refined aspiration technique protocols are improving first-pass revascularization rates and are increasingly used as standalone or combined approaches alongside stent retrievers.
• Combined aspiration and stent retriever approaches: Techniques combining direct aspiration with stent retriever deployment are gaining adoption at high-volume stroke centers due to evidence supporting improved first-pass and overall revascularization success rates.
• Aspiration pump systems: Dedicated aspiration pump canisters supporting large-bore catheter thrombectomy are an established and growing procedural category, contributing to the market alongside access and retrieval devices.
• Expanding treatment time windows: Clinical research into extended treatment windows beyond the traditional eight-hour threshold is ongoing, and positive findings could meaningfully expand the eligible patient population and increase total procedure volumes.
• Stroke center network expansion: Infrastructure investment to build out regional stroke center networks, particularly in emerging markets and suburban and rural areas, is the primary pathway to closing the gap between eligible patients and treated patients.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• Where are the largest and fastest-growing opportunities across stent retrievers, aspiration catheters, and aspiration pump canisters within the global thrombus management market through 2032?
• How has clinical evidence from MR CLEAN, ESCAPE, EXTEND-IA, and SWIFT PRIME shaped physician adoption of mechanical thrombectomy, and what is the trajectory toward standard of care status?
• How large is the underpenetrated patient population for mechanical thrombectomy, and what would closing the current access gap mean for unit volume and market value growth?
• What is the impact of treatment window constraints and limited stroke center availability on the pace of market expansion, and what infrastructure changes could unlock growth?
• How are advances in aspiration technique and next-generation stent retriever design improving procedural efficiency and expanding clinical adoption across different operator experience levels?
• Which companies lead each device segment and what are their clinical differentiation strategies and innovation priorities?
• What is the outlook for combined aspiration and stent retriever procedural approaches, and how is this shaping device purchasing and procedural training at high-volume centers?
• What are the key risks to market growth, including treatment window limitations, access infrastructure gaps, and reimbursement variability across global markets?

The Global Neurovascular Thrombus Management Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail. Use it to quantify demand, benchmark competitors, prioritize product development investments, and plan for growth across a market defined by strong clinical evidence, a large underpenetrated patient population, and expanding global infrastructure.

TABLE OF CONTENT

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Neurovascular Thrombus Management Market

• 12.1 Executive Summary
  • 12.1.1 Global Neurovascular Thrombus Management Market Overview
  • 12.1.2 Competitive Analysis
  • 12.1.3 Procedures Included
  • 12.1.4 Markets Included
  • 12.1.5 Regions Included
• 12.2 Introduction
• 12.3 Procedure Numbers
• 12.4 Market Overview
  • 12.4.1 By Segment
  • 12.4.2 By Region
• 12.5 Market Analysis And Forecast
  • 12.5.1 Total Neurovascular Thrombus Management Market
  • 12.5.2 Stent Retriever Market
  • 12.5.3 Aspiration Catheter Market
  • 12.5.4 Aspiration Pump Canister Catheter Market
• 12.6 Drivers And Limiters
  • 12.6.1 Market Drivers
  • 12.6.2 Market Limiters
• 12.7 Competitive Market Share Analysis

Appendix

LIST OF CHARTS

• Chart 12-1: Neurovascular Thrombus Management Market, Global, 2025 & 2032
• Chart 12-2: Neurovascular Thrombus Management Procedures, Global, 2025
• Chart 12-3: Neurovascular Thrombus Management Procedures by Region, Global, 2022 - 2032
• Chart 12-4: Neurovascular Thrombus Management Market by Segment, Global, 2022 - 2032
• Chart 12-5: Neurovascular Thrombus Management Market by Region, Global, 2022 - 2032
• Chart 12-6: Leading Competitors, Neurovascular Thrombus Management Market, Global, 2025

LIST OF FIGURES

• Figure 12-1: Neurovascular Thrombus Management Procedures Covered
• Figure 12-2: Neurovascular Thrombus Management Markets Covered
• Figure 12-3: Neurovascular Thrombus Management Regions Covered, Global (1 of 2)
• Figure 12-4: Neurovascular Thrombus Management Regions Covered, Global (2 of 2)
• Figure 12-5: Neurovascular Thrombus Management Procedures by Segment, Global, 2022 - 2032
• Figure 12-6: Neurovascular Thrombus Management Procedures by Region, Global, 2022 - 2032
• Figure 12-7: Neurovascular Thrombus Management Procedures by Country, North America, 2022 - 2032
• Figure 12-8: Neurovascular Thrombus Management Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 12-9: Neurovascular Thrombus Management Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 12-10: Neurovascular Thrombus Management Procedures by Country, Western Europe, 2022 - 2032
• Figure 12-11: Neurovascular Thrombus Management Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 12-12: Neurovascular Thrombus Management Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 12-13: Neurovascular Thrombus Management Procedures by Country, Middle East, 2022 - 2032
• Figure 12-14: Neurovascular Thrombus Management Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 12-15: Neurovascular Thrombus Management Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 12-16: Neurovascular Thrombus Management Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 12-17: Neurovascular Thrombus Management Procedures by Country, Africa, 2022 - 2032
• Figure 12-18: Neurovascular Thrombus Management Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 12-19: Neurovascular Thrombus Management Market by Region, Global, 2022 - 2032 (US$M)
• Figure 12-20: Market Value by Region, Neurovascular Thrombus Management Market, Global, 2022 - 2032 (US$M)
• Figure 12-21: Stent Retriever Market, Global, 2022 - 2032
• Figure 12-22: Units Sold by Region, Stent Retriever Market, Global, 2022 - 2032
• Figure 12-23: Average Selling Price by Region, Stent Retriever Market, Global, 2022 - 2032 (US$)
• Figure 12-24: Market Value by Region, Stent Retriever Market, Global, 2022 - 2032 (US$M)
• Figure 12-25: Aspiration Catheter Market, Global, 2022 - 2032
• Figure 12-26: Units Sold by Region, Aspiration Catheter Market, Global, 2022 - 2032
• Figure 12-27: Average Selling Price by Region, Aspiration Catheter Market, Global, 2022 - 2032 (US$)
• Figure 12-28: Market Value by Region, Aspiration Catheter Market, Global, 2022 - 2032 (US$M)
• Figure 12-29: Aspiration Pump Canister Catheter Market, Global, 2022 - 2032
• Figure 12-30: Units Sold by Region, Aspiration Pump Canister Catheter Market, Global, 2022 - 2032
• Figure 12-31: Average Selling Price by Region, Aspiration Pump Canister Catheter Market, Global, 2022 - 2032 (US$)
• Figure 12-32: Market Value by Region, Aspiration Pump Canister Catheter Market, Global, 2022 - 2032 (US$M)
• Figure 12-33: Leading Competitors, Neurovascular Thrombus Management Market, Global, 2025